BiondVax Pharmaceuticals Ltd. announced that its patent application in the United States titled "Multimeric Multi-Epitope Polypeptides in Improved Seasonal and Pandemic Influenza Vaccines" has completed examination and is allowed for issuance as a patent. The invention covers the use of BiondVax's universal flu vaccine as a prime-boost to the current commercially available flu vaccine. Results from BiondVax's completed clinical trials have shown significantly increased effectiveness against multiple flu strains.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.94 USD | +5.76% | -12.50% | -50.62% |
06-27 | ADRs End Flat; Alarum Technologies Climbs 26% | DJ |
06-17 | Top Premarket Gainers | MT |
1st Jan change | Capi. | |
---|---|---|
-50.62% | 1.29M | |
+16.59% | 45.51B | |
-9.89% | 38.52B | |
+38.08% | 38.13B | |
+27.12% | 30.74B | |
-8.64% | 26.03B | |
+11.81% | 25.92B | |
+45.08% | 14.13B | |
+32.85% | 12.73B | |
-7.19% | 11.29B |
- Stock Market
- Equities
- BVXV Stock
- News Scinai Immunotherapeutics Ltd.
- BiondVax's Universal Flu Vaccine Receives Additional US Patent